title: Cardiovascular risk profile of veteran men beginning androgen deprivation therapy.
abstract: We sought to describe the cardiovascular profile of veteran men before beginning androgen deprivation therapy (ADT), with the eventual benefit of targeting treatments to manage harmful cardiovascular side effects. We performed a secondary analysis with chi-square and Fisher's exact tests for associations between demographics and cardiovascular comorbidities on 375 veteran men diagnosed with prostate cancer. Those who were overweight and current smokers were more likely to be younger, whereas men with a systolic blood pressure >120 mmHg were more likely to be older (all P < 0.05). Men with total cholesterol 180 mg/dL were more likely to be identified in the Hispanic/other/unknown ethnicity category. Interventions to manage cardiovascular risk should focus on preventive lifestyle changes for younger men, and chronic disease management for older men. Men in the smaller Hispanic/other/unknown category are at risk for marginalization within the Veteran Administration system owing to their low numbers and should be closely monitored for cholesterol levels when receiving ADT.
authors.affiliation: UCLA School of Nursing, Los Angeles, California. Electronic address: lindsayakirawilliams@gmail.com.
authors.forename: Lindsay
authors.initials: L
authors.lastname: Williams
authors.affiliation: UCLA School of Nursing, Los Angeles, California.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Hicks
authors.affiliation: Department of Urology, UCLA David Geffen School of Medicine, Los Angeles, California.
authors.forename: Lorna
authors.initials: L
authors.lastname: Kwan
authors.affiliation: Department of Urology, UCLA David Geffen School of Medicine, Los Angeles, California.
authors.forename: Mark
authors.initials: M
authors.lastname: Litwin
authors.affiliation: UCLA School of Nursing, Los Angeles, California.
authors.forename: Sally
authors.initials: S
authors.lastname: Maliski
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use*; D002140:California; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality*; D003430:Cross-Sectional Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment; D012307:Risk Factors; D014728:Veterans
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal